News

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
TMCnet11h
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Apogee plans to conduct Phase 2b trials in asthma and eosinophilic esophagitis (EoE) with trial designs informed by APEX Part B dose optimization as well as the Phase 1b results in asthma. Apogee ...
Three new cancer drugs approved for use for NHS Scotland
Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) ...
Stocktwits on MSN4h
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...
pharmaphorum22h
Leo puts target on Dupixent in US as FDA clears tralokinumab
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab. IL-13 inhibitor ...
The Malaysian Reserve2h
The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan ...
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today ...